Thu, Jul 24, 2014, 9:41 AM EDT - U.S. Markets close in 6 hrs 19 mins

Recent

% | $
Click the to save as a favorite.

Becton, Dickinson and Company Message Board

  • nyctel nyctel Feb 20, 2011 1:35 PM Flag

    Accelr8 Extends Evaluation Period with Novartis

    http://www.genomeweb.com//node/961997?hq_e=el&hq_m=930440&hq_l=4&hq_v=e14918f156

    AXK

    NEW YORK (GenomeWeb News) – Accelr8 Technology disclosed in a filing with the US Securities Exchange Commission last night that its technology evaluation agreement with Novartis Vaccines and Diagnostics has been extended to June 30, 2011.

    Novartis is evaluating the firm's BACcel system for identifying the type and quantity of bacterial pathogens in clinical specimens. The firms inked the initial evaluation agreement in June 2010, though at the time Accelr8 did not name the partner.

    Under an amended letter of intent, Novartis has exclusive rights to evaluate the technology until the end of June 2011. The drug and diagnostics firm will pay Accelr8 an undisclosed fixed amount, under terms of the amended agreement.

    Denver-based Accelr8 said that as of Jan. 31, it has received an aggregate amount of roughly $640,000 from Novartis, and it anticipates receiving "not less than $140,000 more pursuant to these agreements."

    The BACcel system is a rapid bacterial diagnostics system that, according to the firm, can identify bacteria within two hours and their major resistance mechanisms within six hours. Accelr8 has been working on tests for antibiotic resistance detection.

    In Tuesday afternoon trade on the American Stock Exchange, shares of Accelr8 were up 9 percent at $1.77.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
BDX
118.68+0.07(+0.06%)9:40 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.